Servier Egypt launches Tibsovo as first targeted therapy for IDH1-mutated cancers
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The new treatment offers a median overall survival of 29.3 months for eligible AML patients